Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Phase 1 Single Ascending Dose Study
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Neuramedy Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06934941
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Neuramedy Co. Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05790382
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
News
Multiple System Atrophy Pipeline Shows Promise with 22+ Therapies in Development as FDA Grants Fast Track Designations
The global Multiple System Atrophy (MSA) market is experiencing significant growth driven by emerging alpha-synuclein targeting therapies and advanced diagnostic technologies including high-resolution MRI and biomarker identification.